VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2019 | PNH treatment: ravulizumab vs. eculizumab

Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, Leeds Teaching Hospital NHS Trust, Leeds, UK, discusses patient preferences for the treatment of their paroxysmal nocturnal hemoglobinuria (PNH). Dr Hill specifically mentions the results of a patient survey of ravulizumab (alxn1210) and eculizumab. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter